Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNR NASDAQ:CDNA NASDAQ:FLGT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$16.89-0.9%$18.56$2.49▼$41.72$177.68M1.4926,744 shs4,808 shsCDNACareDx$20.52+2.7%$18.91$10.96▼$23.24$1.05B2.49706,566 shs509,678 shsFLGTFulgent Genetics$15.97+1.7%$15.62$13.46▼$31.04$474.51M0.88501,373 shs237,087 shsVCYTVeracyte$41.54+8.0%$33.87$22.61▼$50.71$3.33B1.89910,229 shs962,487 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech0.00%+1.67%-17.56%-41.51%+497.89%CDNACareDx0.00%-8.48%-6.77%+1.73%+13.85%FLGTFulgent Genetics0.00%-1.63%-3.44%-32.99%-22.85%VCYTVeracyte0.00%-4.80%+13.85%+7.58%+31.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$16.89-0.9%$18.56$2.49▼$41.72$177.68M1.4926,744 shs4,808 shsCDNACareDx$20.52+2.7%$18.91$10.96▼$23.24$1.05B2.49706,566 shs509,678 shsFLGTFulgent Genetics$15.97+1.7%$15.62$13.46▼$31.04$474.51M0.88501,373 shs237,087 shsVCYTVeracyte$41.54+8.0%$33.87$22.61▼$50.71$3.33B1.89910,229 shs962,487 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech0.00%+1.67%-17.56%-41.51%+497.89%CDNACareDx0.00%-8.48%-6.77%+1.73%+13.85%FLGTFulgent Genetics0.00%-1.63%-3.44%-32.99%-22.85%VCYTVeracyte0.00%-4.80%+13.85%+7.58%+31.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 1.00SellN/AN/ACDNACareDx 2.00Hold$25.0023.37% UpsideFLGTFulgent Genetics 2.20Hold$27.0067.70% UpsideVCYTVeracyte 2.38Hold$44.836.37% UpsideCurrent Analyst Ratings BreakdownLatest BNR, FLGT, VCYT, and CDNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026VCYTVeracyte UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $52.005/6/2026VCYTVeracyte Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$40.00 ➝ $42.005/5/2026FLGTFulgent Genetics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$30.00 ➝ $15.004/29/2026CDNACareDx BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $28.004/20/2026BNRBurning Rock Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026VCYTVeracyte Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$43.00 ➝ $40.004/13/2026VCYTVeracyte Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/1/2026VCYTVeracyte Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.003/30/2026VCYTVeracyte GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $45.003/27/2026VCYTVeracyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/12/2026VCYTVeracyte Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$77.16M2.28N/AN/A$7.28 per share2.30CDNACareDx$379.80M2.76N/AN/A$5.89 per share3.44FLGTFulgent Genetics$322.67M1.48N/AN/A$35.80 per share0.45VCYTVeracyte$517.15M6.50$1.63 per share25.83$16.57 per share2.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$7.92M-$0.79N/AN/AN/A-10.27%-9.98%-6.69%6/2/2026 (Estimated)CDNACareDx-$21.35M-$0.16N/A67.55N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)FLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)VCYTVeracyte$66.35M$1.0938.5729.68N/A16.25%9.07%8.38%8/5/2026 (Estimated)Latest BNR, FLGT, VCYT, and CDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2026Q1 2026BNRBurning Rock Biotech-$2.2884N/AN/AN/A$19.21 millionN/A5/5/2026Q1 2026VCYTVeracyte$0.34$0.52+$0.18$0.35$130.36 million$139.07 million4/28/2026Q1 2026CDNACareDx$0.11$0.34+$0.23$0.05$102.03 million$117.70 million3/13/2026Q4 2025BNRBurning Rock BiotechN/A-$0.21N/A-$0.21N/A$18.05 million2/27/2026Q4 2025FLGTFulgent Genetics$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million2/25/2026Q4 2025VCYTVeracyte$0.41$0.53+$0.12$0.51$135.79 million$140.64 million2/24/2026Q4 2025CDNACareDx$0.24$0.12-$0.12-$0.08$102.76 million$108.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A2.992.79CDNACareDxN/A3.403.07FLGTFulgent GeneticsN/A5.315.31VCYTVeracyteN/A9.318.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%CDNACareDxN/AFLGTFulgent Genetics48.06%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%CDNACareDx4.40%FLGTFulgent Genetics36.18%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.52 million7.33 millionNot OptionableCDNACareDx74051.66 million49.39 millionOptionableFLGTFulgent Genetics1,31529.75 million18.99 millionOptionableVCYTVeracyte79079.79 million78.68 millionOptionableVCYT, BNR, FLGT, and CDNA HeadlinesRecent News About These CompaniesVeracyte (NASDAQ:VCYT) Shares Up 7.1% - Here's Why13 minutes ago | marketbeat.comWhy Veracyte (VCYT) is a Top Growth Stock for the Long-Term4 hours ago | zacks.comStatutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings AreMay 15 at 12:32 PM | finance.yahoo.comVeracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerMay 15 at 9:15 AM | businesswire.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Recommendation of "Hold" by BrokeragesMay 14, 2026 | americanbankingnews.comState of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYTMay 12, 2026 | marketbeat.comInsider Selling: Veracyte (NASDAQ:VCYT) SVP Sells 10,204 Shares of StockMay 9, 2026 | insidertrades.comAnalysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Solventum Corporation (SOLV)May 8, 2026 | theglobeandmail.comVeracyte, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comVeracyte (NASDAQ:VCYT) SVP Sells $398,160.08 in StockMay 8, 2026 | marketbeat.comVeracyte Inc Earnings Call Signals Profitable GrowthMay 8, 2026 | theglobeandmail.comVeracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 8, 2026 | finance.yahoo.comWhy Veracyte Stock Is Skyrocketing Higher This WeekMay 7, 2026 | fool.comVeracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsMay 7, 2026 | zacks.comVeracyte (NASDAQ:VCYT) Shares Gap Up Following Strong EarningsMay 6, 2026 | marketbeat.comVeracyte earnings loom: Investors watch for TrueMRD launch detailsMay 6, 2026 | investing.comVeracyte: Q1 Earnings SnapshotMay 5, 2026 | sfgate.comVeracyte (VCYT) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comVeracyte Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comVeracyte, Inc. (VCYT) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comVeracyte (VCYT) Beats Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCYT, BNR, FLGT, and CDNA Company DescriptionsBurning Rock Biotech NASDAQ:BNR$16.89 -0.15 (-0.88%) As of 03:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.CareDx NASDAQ:CDNA$20.52 +0.55 (+2.74%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Fulgent Genetics NASDAQ:FLGT$15.96 +0.27 (+1.69%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Veracyte NASDAQ:VCYT$41.54 +3.06 (+7.96%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
